🔎 Trials Near Me

Home › Melanoma › Texas › Houston

Melanoma clinical trials in Houston, TX

59 studies for Melanoma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

RecruitingPhase 1
  • University of Texas MD Anderson Cancer Center, Houston
  • NEXT Houston, Houston
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecruitingObservational studyHealthy volunteers welcome
  • UT MD Anderson Cancer Center, Houston
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

RecruitingPhase 2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478

A Study of BI 3810944 in Patients With Advanced Cancer

RecruitingPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07224425

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

RecruitingPhase 3
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06246916

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

RecruitingPhase 2
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06548789

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

RecruitingPhase 2
  • UT MD Anderson Cancer Center, Houston
Up to age 25 · All sexes · Updated Sep 24, 2026 · NCT07621614

Pan-tumor MRD Study

RecruitingObservational study
  • Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404

Intratumoral N17350 in Advanced Solid Tumors

RecruitingPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

RecruitingPhase 1/2
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

RecruitingPhase 1
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04038619

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

RecruitingPhase 2
  • Local Institution - 0085, Houston
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07492680

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

RecruitingPhase 1/2
  • University of Texas-MD Anderson, Houston
  • Lumi Research, Houston
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07287917

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

RecruitingPhase 1
  • MD Anderson, Houston
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04913285

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

RecruitingPhase 1/2
  • The University of Texas M. D. Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT06683755

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06545682

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

Project: Every Child for Younger Patients With Cancer

RecruitingObservational study
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

RecruitingObservational study
  • M D Anderson Cancer Center, Houston
All ages · All sexes · Updated Aug 21, 2026 · NCT01772771

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

RecruitingPhase 1/2
  • Research Site, Houston
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07115043

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

RecruitingPhase 1/2
  • Houston Methodist Hospital, Houston
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04895709

A Study of MGC026 in Participants With Advanced Solid Tumors

RecruitingPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

RecruitingPhase 1/2
  • The University of Texas, MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

RecruitingPhase 2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT04594187

IDOV-Immune for Advanced Solid Tumors

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06910657

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

RecruitingPhase 1/2
  • M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06060613

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

RecruitingPhase 2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT05704647

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

RecruitingPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 12 to 50 · All sexes · Updated Jul 15, 2026 · NCT03093909

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

RecruitingPhase 2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT04771520

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

RecruitingPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT03947385

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

RecruitingPhase 1
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05039801

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

RecruitingPhase 2
  • USA12-0, Houston
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT06953089

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Recruiting
  • M D Anderson Cancer Center, Houston
Ages 19 and older · All sexes · Updated May 22, 2026 · NCT05053555

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

RecruitingObservational study
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT04751396

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

RecruitingPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT05379985

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

RecruitingPhase 1/2
  • University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT03686124

Neoadjuvant Darovasertib in Primary Uveal Melanoma

RecruitingPhase 3
  • Retina Consultants of Texas - (Houston), Houston
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07015190

Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma

RecruitingObservational study
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT04778449

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

RecruitingPhase 2
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT05026983

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT06660420

Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

RecruitingObservational study
  • M D Anderson Cancer Center, Houston
All ages · All sexes · Updated Apr 16, 2026 · NCT04474301

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Recruiting
  • M D Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT04693377

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

RecruitingPhase 1/2
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06362369

A Study of VET3-TGI in Patients With Solid Tumors

RecruitingPhase 1
  • University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Apr 7, 2026 · NCT06444815

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

RecruitingPhase 2/3
  • The University Of Texas Md Anderson Cancer Center, Houston
All ages · All sexes · Updated Apr 2, 2026 · NCT06581406

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

RecruitingPhase 3
  • Houston Methodist Hospital/Houston Methodist Cancer Center, Houston
Ages 18 and older · All sexes · Updated Feb 25, 2026 · NCT05549297

ACTengine® IMA203 Combined With mRNA-4203

RecruitingPhase 1
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Jan 8, 2026 · NCT06946225

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

RecruitingPhase 3
  • The University of Texas M.D. Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT03567889

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

RecruitingPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT06249048

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RecruitingObservational study
  • Massive Bio SYNERGY-AI site, Houston
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

RecruitingPhase 1/2
  • MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated May 18, 2025 · NCT05970497

BostonGene and Exigent Genomic INsight Study

RecruitingObservational study
  • Oncology Consultants, Houston
Ages 18 and older · All sexes · Updated Feb 17, 2025 · NCT06272864

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

RecruitingPhase 1/2
  • Oncology Consultants, P.A., Houston
  • The University of Texas M. D. Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Feb 13, 2025 · NCT05669430

A Study of IBI363 in Subjects with Advanced Solid Malignancies

RecruitingPhase 2
  • MD Anderson Cancer Center-University of Texas, Houston
  • Oncology Consultants P.A., Houston
Ages 18 and older · All sexes · Updated Dec 19, 2024 · NCT06281678

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
  • The University of Texas MD Anderson Cancer Center, Houston
Ages 18 and older · All sexes · Updated Nov 27, 2024 · NCT03860883

About Melanoma

Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.

More about Melanoma on MedlinePlus

Melanoma trials in other cities

Other studies in Houston

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.